Perioperative terlipressin (Tp) during living donor liver transplantation (LDLT) has been shown to reduce intraoperative portal pressures and improve renal function. Its role and safety profile have never been evaluated in a double-blind randomized controlled trial (RCT). The aim was to evaluate the hemodynamic effects, clinical benefits, and safety of perioperative Tp infusion in adult LDLT. This was a single-center double-blind RCT. Consenting adults with chronic liver disease and low risk of posttransplant renal dysfunction undergoing their first LDLT were randomized. The study group (terlipressin group [TpG]) received an initial bolus of Tp during surgery followed by a Tp infusion for 72 hours in the postoperative period. The placebo group (PbG) received a saline infusion. The primary endpoint was portal pressure after arterial reperfusion. Multiple intraoperative and postoperative variables served as secondary endpoints. A total of 41 patients were enrolled in the trial (TpG, 21; PbG, 20) . There were no significant differences in intraoperative portal pressures, blood loss, fluid requirement, vasopressor requirement, or urine output. Peak intraoperative and end of surgery lactate levels were significantly higher in the Tp group. There was no difference in postoperative liver function tests. Incidence of acute kidney injury as assessed by Risk, Injury, Failure, Loss, and End-Stage Kidney Disease criteria was lower in the Tp group (27% versus 60%; P 5 0.04). The TpG had less postoperative ascites, a lower need for percutaneous interventions, and a shorter hospital stay. Incidence of bradycardia requiring pharmacological intervention and withdrawal from study was significantly higher in the TpG. In conclusion, this study has not demonstrated a reduction in postreperfusion portal pressure with Tp. However, Tp infusion reduced postoperative ascitic drain output resulting in less frequent percutaneous interventions and reduced hospital stay. Intraoperative hyperlactatemia and symptomatic bradycardia are major concerns. Its use should be restricted to patients with high-volume ascites, and it needs close monitoring during drug infusion.
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Terlipressin (Tp) is a synthetic long-acting analogue of vasopressin. It induces selective splanchnic arteriolar vasoconstriction, leading to a decrease of splanchnic blood flow thus decreasing portal hypertension in patients with cirrhosis.
(1) It also shifts blood from the splanchnic to the systemic circulation leading to improved renal blood flow. Tp has been used in the management of variceal bleeding (2) and in type 1 hepatorenal syndrome (HRS). (3) Tp in the setting of living donor liver transplantation (LDLT) has several theoretical benefits. Reduction of portal flow and portal pressure during recipient hepatectomy may decrease blood loss. It may decrease the extent of bowel congestion following portal vein clamping. It may reduce the need for surgical maneuvers to decrease graft portal flow such as splenic artery ligation or hemiportocaval shunt. Its use in the posttransplant period may decrease graft injury due to portal hyperperfusion, decrease residual portal hypertension, and improve renal blood flow. All these factors have the potential to decrease morbidity and improve outcomes.
There have been several studies recently investigating the role of Tp in LDLT. (4) (5) (6) Improved renal function has been reported with Tp, whereas 1 study reported shortened intensive care unit (ICU) stay. (5) However, these trials were open-label studies, which cannot completely rule out bias. In addition, none of these studies have critically reviewed the safety profile of Tp in the early posttransplant setting. We report the results of the first double-blind randomized controlled trial (RCT) of the use of Tp in adult LDLT with a particular emphasis on its safety profile in this setting.
Patients and Methods
This was a double-blind RCT. Adults (age > 18 years) undergoing their first LDLT were considered for inclusion in the trial. Patients undergoing liver transplantation for acute liver failure, multiorgan transplants, those with high risk of posttransplant renal dysfunction (PTRD; serum creatinine >1.5 mg/dL at time of transplant), and those with significant cardiac morbidity (coronary artery disease or cirrhotic cardiomyopathy) were excluded. Eligible patients were approached for participation in the trial, and written informed consent was taken. The trial protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki, received a priori approval from the institutional ethics committee, and was registered with Clinical Trial RegistryIndia (CTRI/2013/10/004072).
Recipients underwent intravenous induction with propofol and were maintained on inhalational anesthesia. All recipients had invasive blood pressure monitoring with a radial arterial line. A central venous catheter was placed in the right internal jugular vein for fluid infusion and monitoring of central venous pressure (CVP). Cardiac output monitoring using pulse contour cardiac output analysis was only used in selected high-risk cases. Intraoperative monitoring included serial arterial blood gases, thromboelastogram, and standard laboratory tests. As a protocol, we follow a policy of restrictive fluid usage using colloids and crystalloids during the intraoperative period to reduce venous congestion and blood loss. (7) The surgical technique involved a cava-preserving recipient hepatectomy. A right lobe graft without a middle hepatic vein with back-table reconstruction of the anterior sector venous drainage was the most commonly used graft. Complete caval clamping or venovenous bypass was not necessary for any patient. Portal pressure was measured by direct puncture of the recipient portal vein before completion of the recipient hepatectomy and after arterial anastomosis. CVP was recorded at the same time. Postoperatively, patients were electively ventilated overnight and extubated the next morning after satisfactory results for blood gases, laboratory tests, and ultrasound Doppler study. Patients were managed in the ICU/step-down facility until they were hemodynamically stable with good graft and systemic organ function and then transferred to the surgical ward. Patients had daily Doppler studies from days 1-5 and later, when clinically indicated. They were discharged from the hospital once they were clinically well and on stable immunosuppression.
Consenting patients were randomized after the start of surgery after a complete laparotomy. Randomization was by a computer-generated random number sequence. Patients were randomized in a 1:1 ratio to the trial group or placebo group (PbG) using sealed envelopes. Patients allocated to the study group (terlipressin group [TpG]) received an initial intravenous bolus of Tp (Remistyp, Ferring Pharmaceuticals, Saint-Prex, Switzerland; 1 mg in 50 mL saline over 30 minutes) followed by a continuous infusion of Tp at the rate calculated for the patient's weight for 72 hours (calculated dose of 2 lg/kg/hour) for 72 hours. Patients randomized to receive a placebo (Pb) received an initial saline bolus followed by a saline infusion at the rate calculated for the patient's weight for 72 hours. A research nurse not directly involved in the care of the patient randomized the patient and prepared the trial medication. The anesthetic, surgical, and intensive care teams; the nursing staff; and the patient were blinded to the care unit; INR, international normalized ratio; LDLT, living donor liver transplantation; MELD, Model for End-Stage Liver Disease; Pb, placebo; PbG, placebo group; POD, postoperative day; PTRD, posttransplant renal dysfunction; SEM, standard error of the mean; RCT, randomized controlled trial; RI, resistance index; RIFLE, Risk, Injury, Failure, Loss, and End-Stage Kidney Disease; SD, standard deviation; SFSS, small-for-size syndrome; Tp, terlipressin; TpG, terlipressin group; V1, vasopressin receptors type 1.
allocation. The patient was unblinded and the trial medication was stopped if the patient had complications attributable to Tp (bradycardia, hypertension, severe abdominal pain, skin changes) or when it was felt that Tp was indicated (PTRD and/or high portal flows).
DATA ANALYSIS
Data in the form of patient demographics, preoperative indicators of disease severity, and intra-operative variables were collected. Postoperative variables including daily urine output, drain output, blood investigations, Doppler indices, complications, need for intervention, drug-related adverse effects, and need for termination of trial medication were recorded. The primary endpoint was portal pressure measured by direct puncture of the portal vein after arterial anastomosis. Secondary endpoints included multiple intraoperative and postoperative outcome variables. A review of our previous portal pressure data suggested that the mean portal pressure after arterial reperfusion was 12 mm Hg (standard deviation [SD], 2 mm Hg). If a decrease in mean portal pressure by 20% is considered clinically relevant, the calculated minimum sample size is 16 per study arm (alpha set at 0.05 and power set at 80% [2-tailed effect]). Sample size for each arm was set at 20 to account for study withdrawals or protocol breaches. Data were analyzed on an intention-to-treat basis. Continuous variables were presented as mean and SD. Discrete variables were presented as percentages. Continuous variables were compared with Student t test or Mann-Whitney U test. Discrete variables were compared using chi-square test with Fisher's exact correction where necessary.
Results
Between July 2012 and Dec 2013, 74 adult patients underwent LDLT (Fig. 1) . A total of 33 patients were excluded as shown in Fig. 1 . Of the 61 patients who were approached for participation in the trial, 44 consented. A total of 41 patients were randomized to either the study group (TpG) or PbG. Three patients who had consented for the study were not randomized due to intraoperative findings of sclerosing peritonitis with severe portal hypertension in 2 patients and an acute portal venous thrombosis in a third patient. All recipients received grafts from close family relatives and were blood group compatible.
The preoperative clinical details and preoperative data of the 2 groups are compared in Table 1 . Both groups were well-matched for age, sex, etiology, Model for End-Stage Liver Disease (MELD) score, and final graft-to-recipient weight ratio (GRWR). All 41 patients received the allocated trial medication. Trial medication was not stopped for any patient during the intraoperative period. There was no difference in estimated blood loss, transfusion requirements, vasopressor requirement, fluid requirements, intraoperative portal pressures, and urine output. TpG had higher blood lactate levels throughout the operation as evidenced by significantly higher peak and end lactate levels.
All patients had Doppler studies from postoperative days (PODs) 1 to 5 as per our clinical protocol. Patients in TpG had lower portal flow velocities on Doppler on POD 1 (46 6 16 versus 60 6 22 cm/sec P 5 0.04). This, however, had equalized by day 2. Both groups had similar ICU stay (Table 1 ). There was no significant difference in the incidence of smallfor-size syndrome (SFSS) (8) or vascular, biliary, or infective complications between the 2 groups. There was a statistically higher need for percutaneous interventions in the PbG, which was primarily for drainage of pleural effusions or intra-abdominal noninfective collections (45% versus 14%; P 5 0.03).
A significantly higher percentage of the PbG developed acute kidney injury (AKI; risk category according to Risk, Injury, Failure, Loss, and End-Stage Kidney Disease [RIFLE] classification). No patients needed renal replacement therapy. In 2 patients who had persistent oliguria associated with high portal flow velocities on POD 1, the treating team felt that Tp was warranted. In both of these patients, trial medication was stopped, and they were started on a low dose of Tp. Both patients were found to have received Pb on unblinding. Drain output was lower in the TpG throughout the first posttransplant week. A subgroup analysis of patients with more than 1 L of ascites at transplant showed that patients in TpG had significantly lesser drain output on PODs 1, 4, and 5 (Fig.  2) . The overall hospital stay was shorter in the TpG (18 versus 21 days; P 5 0.03). There was no inhospital mortality. One patient in the TpG who needed an aortic arterial conduit developed late hepatic artery thrombosis on day 35. He died of biliary sepsis at 2.5 months after transplantation.
DRUG-RELATED ADVERSE EFFECTS AND TRIAL WITHDRAWALS
No patient developed drug-related adverse events in the intraoperative period. Recurrent bradycardia requiring pharmacological intervention was the most significant drug-related adverse effect seen in TpG (24% versus 0%, P 5 0.05; Table 2 ). It was recognized in POD 1 in each of these patients. Other adverse effects were equally distributed in both groups. The study drug was withdrawn in 3 patients in the Tp group: 2 patients for bradycardia alone on POD 1 and 1 patient for bradycardia with hypertension needing glyceryl trinitrate infusion on POD 2. Three patients in the PbG had their trial medication withdrawn in the postoperative period. These included the 2 patients who were started on Tp (discussed earlier) and 1 patient who developed peripheral cyanosis and skin changes in the lower extremities (POD 2), which was considered to be a Tp-related adverse effect.
Discussion
Patients with cirrhosis have a hyperdynamic circulation that is characterized by splanchnic vasodilatation and shifting of blood from systemic to splanchnic circulation.
(1) Tp, a long-acting synthetic analogue of vasopressin, selectively acts on the vasopressin receptors type 1 (V1) receptors in the vascular endothelial cells causing vasoconstriction. Its hemodynamic effects include increased peripheral vascular resistance, decreased cardiac output, selective splanchnic vasoconstriction, reduced portal hypertension, and improved renal blood flow. (9) Wagener et al. reported that Tp induced an 11% reduction in portal pressure and a 25% reduction in portal flow during liver transplantation. (10) Tp is routinely used in patients with cirrhosis for variceal bleeding and type 1 HRS. (11) It has been suggested that a continuous Tp infusion reduced portal venous pressure effectively with less fluctuation compared with bolus injections. (12, 13) We have also used continuous infusion rather than bolus doses in our study.
Adult LDLT involves the transplantation of a small-sized graft, usually half the standard liver volume. The graft regenerates rapidly over the first 3 months after transplant. (14) SFSS is defined as a graft injury due to portal hyperperfusion, which continues to be a problem in adult LDLT. (8) Measures to improve donor safety such as the use of left lobe grafts further increase the risk of SFSS. (15, 16) It has been hypothesized that Tp can improve early posttransplant outcomes by reducing graft portal hyperperfusion and NOTE: Data are given as n (%) or mean 6 SD. *Significant at P < 0.05.
improving renal perfusion: a real "bridge over transplantation" rather than just being a "bridge to transplantation." (17) Several studies have investigated the role of Tp in adult LDLT. Mukhtar et al. reported reduced portal pressures, better renal function, and decreased drain output with Tp. (6) Other studies have reported reduced vasopressor requirements, better posttransplant renal function, and shorter ICU stay with perioperative Tp. (5, 6, (18) (19) (20) However, these were all unblinded studies, so inadvertent bias in assessing outcomes cannot be ruled out. In addition, there has not been any discussion regarding the adverse effects of Tp usage in this setting. It is unclear whether no observed side effects occurred or whether researchers did not actively look for them. A recent meta-analysis of Tp in LDLT highlighted both the nonblinded aspect of these studies and the lack of any adverse effects-related information. (21) Our data attempt to bridge some of these deficiencies. Our trial investigated the role of routine usage in standard risk adults having their first LDLT. We excluded patients at an increased risk of PTRD from the trial because the benefit of perioperative Tp in such patients is well-recognized.
Our study did not demonstrate significant differences in portal pressures between the 2 groups, both prior to recipient hepatectomy and after reperfusion. We had not enrolled or stratified patients based on the severity of portal hypertension, hence both groups were heterogeneous. Low postreperfusion portal pressures and good graft quality also means that reduction in portal flow may not be directly reflected in reduced portal pressures. Comparison of portal flow volumes may have been useful in assessing the effect of Tp better and should be considered in future studies.
One interesting finding in our study was that the blood lactate levels were consistently elevated in the TpG. This continued in the postoperative period, with these patients demonstrating a slower rate of fall in blood lactate. This is, however, contrary to previous studies, all of which had reported no difference in blood lactate levels. (6, 19) Possible reasons for this divergent finding in our study could be our policy of restrictive fluid usage or a relatively higher dose of Tp used in our study. Because fluid infusion is based on CVP monitoring (trends in CVP rather than an absolute value), urine output, oxygen exchange, and cardiac output monitoring (in some patients), significant hypovolemia is unlikely. Hence, though a restrictive fluid policy may contribute to the hyperlactatemia seen in the TpG, it may not be the only reason. The clinical significance of hyperlactatemia in the absence of other signs of poor tissue perfusion is unclear since the postoperative course of patients in both groups was good. An interesting consequence of this was that additional out-of-protocol Doppler examinations were undertaken by the treating team to rule out hepatic arterial thrombosis as the cause for hyperlactatemia in the Tp group.
PTRD after liver transplantation is common and is usually of the "risk" category according to the RIFLE classification. (22) It is usually multifactorial secondary to prolonged surgery, intraoperative blood loss, lowgrade perioperative sepsis, or tacrolimus therapy. A
FIG. 2.
Comparison of total drain output (days 1-7) between patients with more than 1 L ascites at surgery. TpG (n 5 10), PbG (n 5 8). Tp group had significantly lesser drain volumes on days 1, 4, and 5. Mann-Whitney U test (*P < 0.05). NOTE: Data are given as n (%). *Significant bradycardia was defined as heart rate below 50 beats per minute, needing pharmacological intervention and/or withdrawal of trial medication. † New-onset hypertension was defined as diastolic readings greater than 90 mm Hg needing the addition of antihypertensive medications, in a previously nonhypertensive patient after excluding other causes including inadequate analgesia and anxiety. majority of these resolved spontaneously over the first posttransplant week. Persistent AKI beyond the first week is very uncommon in our program, and the need for posttransplant renal replacement therapy in our program is <5%. Our study supports previously published data of better renal function in TpG even though enrolled patients were at low risk of PTRD. Ideally, comparing Tp usage in high-risk patients is necessary; although given that most centers now use this drug in patients at high risk of PTRD, setting up a RCT in this patient subgroup may be difficult. We also found that Tp suppressed postoperative ascitic production particularly in patients with a high preoperative volume of ascites. This may be due to reduced splanchnic blood flow and better renal function, and it has positive implications for their postoperative recovery. (23) The safety profile of Tp in patients with cirrhosis has been extensively investigated. Ioannou et al. reported a meta-analysis of over 1500 patients given either Tp or Pb and found no increased mortality with Tp. (24) Safety of Tp usage in patients with cirrhosis has been confirmed even in the outpatient setting. (25) The most common side effects of Tp are bradycardia, digital pallor, abdominal cramps, and diarrhea. (11) Significant uncorrected cardiovascular disease was identified as the risk factor for cardiac complications. Digital gangrene, extensive cutaneous necrosis, bowel ischemia, (26) and hyponatremia (27) have also been described. We found significantly higher incidence of bradycardia and hypertension with Tp. Severe bradycardia in the postoperative period requiring pharmacological intervention was the indication for trial drug withdrawal in 3 patients. It is possible that the myocardium is sensitized to the effects of Tp in the postoperative setting due to the combined effects of anesthesia, long surgery, and ischemia/reperfusion injury. We recommend careful and restrained use of this drug perioperatively and for close electrocardiogram monitoring during this period.
The main strength of this RCT is its double-blind nature ensuring that there is no risk of bias in reporting. We have shown that Tp is particularly useful in patients with a large volume of ascites. It also reduces the need for interventions and shortens hospital stay. We have also reported for the first time the risk of perioperative bradycardia with Tp usage, which mandates its administration under close monitoring. The drawbacks of the study were that the planned primary endpoint was not achieved and that we did not measure portal blood flow.
To conclude, routine perioperative use of Tp is not recommended in low-risk LDLT recipients. In patients with a large volume of ascites, its use may reduce postoperative ascitic drain output and decrease the need for percutaneous interventions. Perioperative Tp infusion is associated with hyperlactatemia and an increased risk of bradycardia and hypertension and should be administered under close monitoring in an ICU/high-dependency unit setting.
